Neurotune: Linking brain and brawn

As the population ages, sarcopenia - loss of skeletal muscle mass - is an increasingly important unaddressed problem. Neurotune AG thinks neurotrypsin could serve both as a biomarker and therapeutic target for the disease and that its neurotrypsin inhibitors also may work in stroke, brain trauma and schizophrenia.

Neurotune CSO Peter Sonderegger led the group

Read the full 546 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE